Stock Information
Palisade Bio Inc (PALI)
Ticker Symbol: PALI
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $362.78 mil
Piotroski score: 4
PE Ratio: N/A
EPS (TTM): -0.64
Revenue (TTM): $0.00 M
Dividend Yield: N/A
ROE: -33.47%
Latest News
-
Palisade Bio To Present Four Presentations At United European Gastroenterology Week 2026 For Its PALI-2018 Program
Mon, Sep 28, 2026 8:53 AM
-
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
Sun, Sep 27, 2026 5:01 PM
-
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Wed, Sep 23, 2026 12:45 PM
-
Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative Colitis
Wed, Sep 23, 2026 8:47 AM
-
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
Wed, Sep 23, 2026 7:01 AM
-
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
Tue, Sep 22, 2026 12:35 PM
-
Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year
Tue, Sep 22, 2026 8:36 AM
-
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Mon, Sep 21, 2026 1:00 PM
Key Financials
Financial data not available
